Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 7,035,000 shares of common stock of Forty Seven, Inc. Forty Seven’s common stock is listed on The NASDAQ Global Select Market under the symbol “FTSV.”
Forty Seven is a clinical stage immuno-oncology company focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. Forty Seven is based in Menlo Park, California.
The Davis Polk corporate team included partners Sarah K. Solum and Bruce K. Dallas, associates Bryan M. Quinn, Dongbiao Shen and Lucas Tejwani and summer law clerk Bree Gong. Partner Rachel D. Kleinberg and associate M. Brett Cameron provided tax advice. Partner David R. Bauer and associate Paul S. Lee provided intellectual property advice. Members of the Davis Polk team are based in the Northern California and New York offices.